 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 25, 2022 GLOBE NEWSWIRE -- Molecular Partners AG SIX: MOLN; NASDAQ: MOLN, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in two upcoming healthcare investor events in March, 2022. In addition, the Company will publish its full year 2021 annual report on March 15 and hold an investor conference call on March 16, 2021. 